Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial

Capecitabine and docetaxel have single-agent activity in upper gastrointestinal tumours, and have together demonstrated preclinical synergy and a survival benefit in breast cancer, and high response rates in first-line metastatic gastric cancer. This trial assessed the efficacy, safety and feasibili...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenzen, S, Duyster, J, Lersch, C, von Delius, S, Hennig, M, Bredenkamp, R, Peschel, C, Lordick, F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361804/
https://www.ncbi.nlm.nih.gov/pubmed/15942631
http://dx.doi.org/10.1038/sj.bjc.6602645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361804/
https://www.ncbi.nlm.nih.gov/pubmed/15942631
http://dx.doi.org/10.1038/sj.bjc.6602645

Ejemplares similares